Sanofi has secured global exclusive rights to Kali Therapeutics' trispecific antibody KT501 for autoimmune diseases, including a first in human program for rheumatoid arthritis. The company has also ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidApproval in ...
Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...
Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results